A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 1011-1017

  Moosig, Frank ^a   Bremer, Jan Phillip ^a   Hellmich, Bernhard ^b   Holle, Julia Ulrike ^a   Holl Ulrich, Konstanze ^c   Laudien, Martin ^d   Matthis, Christine ^c   Metzler, Claudia ^e   Nölle, Bernhard ^d   Richardt, Gert ^f   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e Barmherzige Brüder Hospital   (Germany)

^f Heart Centre Bad Segeberg Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BLADDER CANCER; BREAST CANCER; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HEART FAILURE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MORTALITY; MULTIPLE MYELOMA; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

MULTIDISCIPLINARY TEAM-CARE; OUTCOMES RESEARCH; SYSTEMIC VASCULITIS;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CHURG-STRAUSS SYNDROME; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84877624335     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201531     Document Type: Article

References (29)

1. Vaglio A, Moosig F, Zwerina J. Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin in Rheumatol 2012;24:24-30.
2. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686-93. (Pubitemid 46764061)
3. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58:586-94. (Pubitemid 351294896)
4. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92. (Pubitemid 24065492)
5. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener 's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32. (Pubitemid 30368179)
6. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8. (Pubitemid 24334817)
7. de Groot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener 's granulomatosis. Clin Nephrol 2001;55:31-8. (Pubitemid 32041780)
8. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener 's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66.
9. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17. (Pubitemid 46707128)
10. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome . A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28. (Pubitemid 26041085)
11. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
12. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129:370-4. (Pubitemid 28402791)
13. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-9.
14. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- Syndrome (EGPA) by TNF-alpha blockade. Immunobiology 2002;206:496-501. (Pubitemid 36192908)
15. Herlyn K, Gross WL, Reinhold-Keller E. Longitudinal effects of structured patient education programs for vasculitis patients. Z Rheumatol 2008;67:206-10.
16. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001;40:763-71.
17. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37. (Pubitemid 29065978)
18. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926-35. (Pubitemid 41369124)
19. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8. (Pubitemid 41552527)
20. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003;115:284-90. (Pubitemid 37088190)
21. Mukhtyar C, Guillevin L, Cid MC, et al . EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-17.
22. Loo KL, Ramachandran R, Chow SK, et al. Mononeuritis in Churg-Strauss syndrome in Asians responding to intravenous cyclophosphamide. Rheumatology (Oxford) 2004;43:251-2. (Pubitemid 38219692)
23. Hoi AY, Morand EF. Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. Rheumatology (Oxford) 2003;42:390-1. (Pubitemid 36305636)
24. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther 2009;11:253.
25. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90:19-27.
26. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88:236-43.
27. Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010;62:627-34.
28. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1336-43.
29. Moosig F, Gross WL, Herrmann K, et al. Targeting IL-5 in refractory/relapsing Churg-Strauss Syndrome. Ann Int Med 2011;155:341-3.